Cytosorbents Corp
Cytosorbents Corp (CTSO) Unusual Options Activity Today
Read more
Checking CTSO unusual options activity helps you spot when traders are making outsized bets on Cytosorbents Corp before the broader market catches on. Unusual activity flags contracts trading at multiples of their average daily volume, often signaling informed money positioning ahead of a catalyst. Use our scanner to monitor CTSO unusual options activity today and surface the prints that deserve a second look.
Unusual options flow typically means volume vastly exceeds open interest at a given strike, or total contract volume on a name spikes well above its norm. Watching CTSO unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking CTSO unusual options volume across calls and puts helps you separate hedging from genuinely speculative positioning, especially valuable around earnings, product launches, and macro events.
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy.
| 2.50 | — | 4.80 | 4.80 | 1,000% | 0 | 4 | 0.00% |
| 5.00 | — | 4.80 | 4.80 | 1,000% | 0 | 0 | — |
| 7.50 | — | 0.65 | 0.65 | 1,000% | 0 | 0 | — |
| 2.50 | 0.05 | 5.60 | 2.83 | 1,000% | 0 | 0 | — |
| 5.00 | 1.25 | 8.10 | 4.68 | 327% | 0 | 0 | — |
| 7.50 | 3.70 | 10.60 | 7.15 | 367% | 0 | 0 | — |
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →